6-4-18 ->

J. . YOUD

CALDERDALE & HUDDERSFIELD NHS FOUNDATION TRUST A KEASKIN AUTHORISATION AND RECORD OF AGREEMENT OF NAMED HEALTH PROFESSIONALS TO ADMINISTER MEDICINES UNDER:

## PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF PREDNISOLONE BY

### REGISTERED HEALTHCARE PROFESSIONALS

### EMERGENCY DEPARTMENTS

#### 1. PGD AUTHORISATION

Position	Name	Signature	Date
Acting Clinical Director of Pharmacy	Fiona Smith	Ruh	23/3/17
Executive Director of Nursing	Brendan Brown	Junua M	23/23/18
Medical Director	David Birkenhead	D. Brind	2813/18
Chairman of Medicines Management Committee	Anu Rajgopal		29/3/18

Date	of Patient	Group	Direction:	March	2018
		I			

If revision please tick box  $\sqrt{\phantom{a}}$ 

Valid Until: March 2020

Review Date: September 2019

Approved by the Trust Medicine Management Committee on: .247H MAY 2018

## PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF PREDNISOLONE

BY

#### REGISTERED HEALTHCARE PROFESSIONALS

IN

#### **EMERGENCY DEPARTMENTS**

#### 2. CLINICAL CONDITION

Indication			
Indication	Adults and children 2 years and over, presenting with acute asthma		
Relevant National and Local Guidelines/Information sources	BTS/SIGN Guidance for Asthma 2014 BNF guidance (2014-2015), CHFT Asthma Care Bundle		
Description of Patients included in treatment	Patients presenting with signs of moderate, severe or lifethreatening asthma  Adults  Moderate – increasing symptoms, no features of severe asthma, PEFR > 50%-75% best or predicted  Acute severe – unable to complete sentences in one breath, resp. rate ≥25/min, heart rate ≥110/min, PEFR 33-50% best or predicted  Life-threatening asthma – cyanosis, silent chest, exhaustion, arrhythmias, hypotension, altered conscious level, coma, feeble respiratory effort, peak flow <33% best or predicted, SpO₂ <92%, PaO₂ <8kPa, normal PaCO₂ (4.6-6.0 kPa)  Children  Moderate – able to talk, HR - 2-5yrs ≤140/min, 5-12yrs ≤125/min, >12yrs <110, Resp. Rate – 2-5yrs ≤40/min, 5-12yrs ≤30/min, >12yrs <25/min, PEFR >5yrs >50% predicted/best  Acute Severe – unable to complete sentence in one breath, or too breathless to speak or feed, Heart Rate – 2-5yrs >140/min, >5yrs >125/min. Resp. Rate – 2-5yrs >40/min, >5yrs >30/min PEFR 33-50% best or predicted. SpO₂ <92% Life-threatening asthma – cyanosis, silent chest, poor respiratory effort, fatigue/exhaustion, agitation, confusion, coma, hypotension, PEFR <33% predicted/best (older children). SpO₂ <92%  Any Life-Threatening asthma should be immediately managed by a senior A&E doctor		
Description of Patients excluded from treatment under the terms of this PGD	Known hypersensitivity to prednisolone		
Action if excluded	Refer to ED doctor or Advanced Clinical Practitioner		
Action if patient self excludes/declines	Refer to ED doctor or Advanced Clinical Practitioner		

# PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF PREDNISOLONE BY REGISTERED HEALTHCARE PROFESSIONALS IN EMERGENCY DEPARTMENTS

#### 3. TREATMENT

J. INCATIVICITI			
Name, form and strength of	Prednisolone 5mg tablets		
medicine	Prednisolone 5mg/ml solution		
Legal Status GSL, P, POM	POM		
Dose	Prednisolone Child 2-5yrs – 20mgs Child 6-15yrs – 30mgs Adult - ≥16yrs – 40mgs		
Frequency of administration	Single Dose Only		
Method and route of administration	Oral		
Supporting facilities required	Full Resuscitation Capacity		
Quantity to supply/administer	Single administration only		
Duration of treatment	Single administration only		
Potential side effects	Dyspepsia, other side effects unlikely from stat dose and more likely to be related to long term use.		
Advice to patient/carer	Explain why the drug is being administered and inform of possible side effects and ask patient to inform staff of any change in their condition		
Managing & Reporting Adverse Events	<ul> <li>All suspected adverse drug reactions occurring after treatment following this PGD must be reported to a senior medical practitioner responsible for the area in which the direction is in use</li> <li>The healthcare professional administering/supplying from the PGD must also report the ADR using Trust incident reporting procedure</li> <li>All serious adverse drug reactions should be reported to the MHRA / CSM using the Yellow Card System. Yellow</li> </ul>		
	cards and guidance on its use are available at the back of the BNF or at <a href="https://www.yellowcard.gov.uk">www.yellowcard.gov.uk</a>		
Follow up	Referral back to GP/Respiratory Nurse Specialist as per asthma management plan		
When to refer to doctor	All patients to be seen by a doctor or Advanced Clinical Practitioner		

# PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF PREDNISOLONE BY REGISTERED HEALTHCARE PROFESSIONALS

### IN EMERGENCY DEPARTMENTS

Treatment record	, •	Document in Electronic Patient Records in ED	
Specify method of recording	•	Prescription as PGD	
supply/administration	•	Name, dose and frequency of drug	
sufficient for audit trail		Advice given, verbal or written	
	•	Signed and dated	

#### 4. STAFF

Professional Qualifications	Registered Nurse or Paramedic
	Current NMC or HCPC registration
Any Exceptions to above	Bank & Agency Staff
Specialist competencies, qualifications and experience	Trust PGD training (ED)
Continuing training & education	Update in line with clinical guideline

#### 5. MANAGEMENT AND MONITORING

5. WANAGEMENT AND WONTONING			
Records to be kept for Audit	STORAGE AND RETRIEVAL		
Purposes	<ul> <li>Pharmacy will retain the original signed version of the PGDs</li> <li>Adult – 8 years</li> </ul>		
	<ul> <li>Children (under 18 years) As the requirement is until child is 25 years old or for eight years after child's death and PGDs are not child specific – this would be indefinitely (at least a minimum of 43 years)</li> <li>Division/Author is responsible for keeping the record/retrieval method of those authorised to work under a PGD/signature sheet to comply with the above</li> </ul>		
Date of writing	March 2018		
Name of manager holding record of names of those authorised to work under this PGD	Louise Croxall – Matron, ED		

# PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF PREDNISOLONE BY REGISTERED HEALTHCARE PROFESSIONALS IN EMERGENCY DEPARTMENTS

Names of all authors of PGD	
(to include a Dr or Dentist)	Print Name: Janet Youd
	Title: Emergency Nurse Consultant
	Signature: Janet Jond Date: 2013/18
	Print Name: Dr Mark Davies .
	Title: Emergency Medicine Consultant
	Signature: Date: 21/3/13
Lead Pharmacist involved in	
preparation of PGD	Print Name: Lisa Hodgson
	Signature:
	Date: 23/3/18:
Approval of Clinical Director	
	Print Name: Mark Davies
	Signature:
	Date:

# PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF PREDNISOLONE BY REGISTERED HEALTHCARE PROFESSIONALS IN EMERGENCY DEPARTMENTS

This Patient Group Direction is to be read and agreed and this Authorisation and Record of Agreement signed by all Health Professionals who will administer and/or supply treatment using it. It is the responsibility of each professional to practice only within the bounds of their own competence

A copy of the Patient Group Direction and the original, signed Record of Agreement must be held together by the Ward/Departmental Manager/Community Team Leader.

'I confirm that I have read and understood the content of this Patient Group Direction and that I am willing to work under it within my Professional Code of Practice/Conduct.'

Name of Health Professional	Designation e.g. RGN	Signature of Health Professional	Signature of Ward/Departmental/Area Manager	Date
,				